News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
697,666 Results
Type
Article (39862)
Company Profile (271)
Press Release (657533)
Section
Business (204996)
Career Advice (2019)
Deals (35524)
Drug Delivery (95)
Drug Development (81181)
Employer Resources (170)
FDA (16176)
Job Trends (14892)
News (346247)
Policy (32598)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (4)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (9)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (5)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (6)
2024 Pharm Country Standard (5)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (6)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Standard (1)
Academia (2563)
Accelerated approval (2)
Adcomms (20)
Allergies (78)
Alliances (49695)
ALS (80)
Alzheimer's disease (1337)
Antibody-drug conjugate (ADC) (104)
Approvals (16163)
Artificial intelligence (219)
Autoimmune disease (12)
Automation (14)
Bankruptcy (361)
Best Places to Work (11658)
BIOSECURE Act (19)
Biosimilars (97)
Biotechnology (190)
Bladder cancer (51)
Brain cancer (24)
Breast cancer (241)
Cancer (1856)
Cardiovascular disease (142)
Career advice (1683)
Career pathing (28)
CAR-T (135)
Cell therapy (384)
Cervical cancer (15)
Clinical research (65650)
Collaboration (737)
Compensation (427)
Complete response letters (18)
COVID-19 (2592)
CRISPR (35)
C-suite (193)
Cystic fibrosis (97)
Data (1799)
Decentralized trials (2)
Denatured (17)
Depression (36)
Diabetes (233)
Diagnostics (6330)
Digital health (17)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (107)
Drug pricing (96)
Drug shortages (25)
Duchenne muscular dystrophy (74)
Earnings (86036)
Editorial (30)
Employer branding (21)
Employer resources (146)
Events (111872)
Executive appointments (622)
FDA (17190)
Featured Employer (48)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (6)
Funding (659)
Gene editing (95)
Generative AI (18)
Gene therapy (265)
GLP-1 (672)
Government (4385)
Grass and pollen (4)
Guidances (47)
Healthcare (18813)
Huntington's disease (23)
IgA nephropathy (20)
Immunology and inflammation (98)
Indications (24)
Infectious disease (2715)
Inflammatory bowel disease (132)
Inflation Reduction Act (10)
Influenza (44)
Intellectual property (75)
Interviews (311)
IPO (16515)
IRA (42)
Job creations (3663)
Job search strategy (1433)
Kidney cancer (9)
Labor market (30)
Layoffs (448)
Leadership (14)
Legal (7931)
Liver cancer (70)
Lung cancer (267)
Lymphoma (126)
Machine learning (2)
Management (58)
Manufacturing (256)
MASH (58)
Medical device (13308)
Medtech (13313)
Mergers & acquisitions (19444)
Metabolic disorders (605)
Multiple sclerosis (63)
NASH (16)
Neurodegenerative disease (71)
Neuropsychiatric disorders (23)
Neuroscience (1790)
NextGen: Class of 2025 (6547)
Non-profit (4487)
Northern California (2289)
Now hiring (36)
Obesity (332)
Opinion (203)
Ovarian cancer (65)
Pain (72)
Pancreatic cancer (75)
Parkinson's disease (125)
Partnered (17)
Patents (187)
Patient recruitment (88)
Peanut (45)
People (57319)
Pharmaceutical (67)
Pharmacy benefit managers (18)
Phase I (20464)
Phase II (28922)
Phase III (21531)
Pipeline (863)
Podcasts (45)
Policy (106)
Postmarket research (2564)
Preclinical (8638)
Press Release (64)
Prostate cancer (87)
Psychedelics (30)
Radiopharmaceuticals (243)
Rare diseases (344)
Real estate (5945)
Recruiting (65)
Regulatory (22112)
Reports (43)
Research institute (2322)
Resumes & cover letters (350)
Rett syndrome (3)
RNA editing (2)
RSV (37)
Schizophrenia (61)
Series A (117)
Series B (71)
Service/supplier (13)
Sickle cell disease (49)
Southern California (1995)
Special edition (14)
Sponsored (28)
Startups (3623)
State (2)
Stomach cancer (12)
Supply chain (58)
The Weekly (26)
United States (20221)
Vaccines (643)
Venture capitalists (37)
Webinars (12)
Weight loss (222)
Women's health (31)
Worklife (14)
Date
Today (104)
Last 7 days (548)
Last 30 days (2862)
Last 365 days (33969)
2025 (6707)
2024 (35330)
2023 (40180)
2022 (51287)
2021 (55834)
2020 (54153)
2019 (46641)
2018 (35123)
2017 (32222)
2016 (31629)
2015 (37706)
2014 (31454)
2013 (26499)
2012 (28770)
2011 (29426)
2010 (27525)
Location
Africa (720)
Alabama (48)
Alaska (7)
Arizona (215)
Arkansas (13)
Asia (37823)
Australia (6198)
California (5269)
Canada (1815)
China (431)
Colorado (238)
Connecticut (253)
Delaware (120)
Europe (81162)
Florida (780)
Georgia (182)
Idaho (58)
Illinois (477)
India (23)
Indiana (283)
Iowa (8)
Japan (133)
Kansas (100)
Kentucky (23)
Louisiana (7)
Maine (60)
Maryland (802)
Massachusetts (3979)
Michigan (206)
Minnesota (360)
Mississippi (2)
Missouri (73)
Montana (27)
Nebraska (25)
Nevada (54)
New Hampshire (62)
New Jersey (1487)
New Mexico (28)
New York (1502)
North Carolina (888)
North Dakota (7)
Northern California (2289)
Ohio (184)
Oklahoma (13)
Oregon (34)
Pennsylvania (1189)
Puerto Rico (8)
Rhode Island (24)
South America (1097)
South Carolina (16)
South Dakota (1)
Southern California (1995)
Tennessee (88)
Texas (776)
Utah (160)
Virginia (126)
Washington D.C. (58)
Washington State (497)
West Virginia (3)
Wisconsin (48)
697,666 Results for "remegen biosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
RemeGen Showcases Research Results at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, Highlighting Its Prolific Innovation in Global Cancer Treatment
RemeGen Co., Ltd. (“RemeGen” or “the Company”) (9995.HK, SHA: 688331), a commercial-stage biotechnology company, showcased its innovation in the field of global cancer treatment at the American Society of Clinical Oncology Annual Meeting (ASCO 2024) held in Chicago from May 31-June 4, 2024.
June 5, 2024
·
4 min read
Policy
RemeGen’s Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren’s Syndrome
RemeGen Co. Ltd., a commercial-stage biotechnology company, obtained Fast Track Designation by the United States Food and Drug Administration recently for its innovative BLyS/APRIL dual-target fusion protein drug, Telitacicept, independently developed by RemeGen for the treatment of patients with primary Sjögren’s syndrome.
April 2, 2024
·
3 min read
RemeGen Reports Proof-of-Concept Phase I/II Clinical Study Results for Self-Developed, Potential First-in-Class Antibody-Drug Conjugate RC88
RemeGen Co., Ltd. (“RemeGen” or “the Company”) (9995.HK, SHA: 688331), a commercial-stage biotechnology company, presented the results of the first-in-human, single-arm, open-label, multi-center Phase I/II study evaluating RC88 in patients with MSLN-expressing advanced solid tumors on June 3, at the American Society of Clinical Oncology Annual Meeting (ASCO 2024) held in Chicago from May 31-June 4, 2024.
June 3, 2024
·
4 min read
Drug Development
RemeGen Completes Patient Enrollment in Two Phase III Clinical Trials Using Telitacicept for Treatment of IgA Nephropathy and Primary Sjögren’s Syndrome
RemeGen Co. Ltd., a commercial-stage biotechnology company, recently announced significant progress of Telitacicept, that two Phase III clinical trials in China for the treatment of IgA nephropathy and primary Sjögren’s syndrome have completed patient enrollments.
May 21, 2024
·
3 min read
RemeGen Announces Continued Inclusion of Telitacicept and Disitamab Vedotin in China National Reimbursement Drug List, Ensuring Continuous Accessibility of Innovative Drugs for More Patients
RemeGen Co. Ltd. (“RemeGen” or “the Company”) (9995.HK, SHA: 688331), a commercial-stage biotechnology company, has recently confirmed that under the 2023 simple renewal mechanism of China National Healthcare Security Administration (NHSA), on January 1, 2024, the updated National Reimbursement Drug List (NRDL) will continue to include Telitacicept (RC18) and Disitamab Vedotin (RC48) for the next two-year agreement.
December 18, 2023
·
6 min read
Press Releases
Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025
March 13, 2025
·
1 min read
Press Releases
TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference
March 10, 2025
·
2 min read
BioCapital
RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024
RemeGen Co. Ltd. recently gave an oral presentation on an interim analysis of the evaluation of the Company’s proprietary Disitamab Vedotin, an investigational anti-HER2 antibody-drug conjugate targeting prevalent solid tumor cancers with significant unmet medical needs, at the European Congress on Gynaecological Oncology held in Barcelona from March 7-10, 2024.
March 10, 2024
·
4 min read
Press Releases
Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval
February 24, 2025
·
4 min read
Press Releases
Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock
February 18, 2025
·
4 min read
1 of 69,767
Next